Welcome to AtriAN
AtriAN Medical
Restoring Rhythm through Science
Mission & Vision
Resolving Atrial Fibrillation at its origin
Current therapies are failing patients and their physicians. Medication fails 70% of the time, and ablations fail 30% within the first year and 50% within three. We are targeting the cardiac autonomic nervous system which should lead to a more durable solution significantly reducing the need for repeat procedures.
TECHNOLOGY
A Disruptive Approach to Rhythm restoration
First, we navigate to the heart’s epicardial (outside) surface, where the errant signals originate in specialized neurons. Secondly, we use new and non-thermal energy (PFA) to disable the neurons permanently.
THE DISRUPTION
AtriAN’s Business Pathway
Growing Market
Atrial Fibrillation is a large and quickly growing condition. Unfortunately, there is yet to be a perfect solution for its resolution. AtriAN’s mission is to change this for patients and their physicians.
Robust and Innovative Intellectual Property (IP)
The idea and technology were conceived and first developed at the Mayo Clinic (Rochester, MN, USA) by Dr. Sam Asirvatham with issued patents across the globe. We continue to innovate the technology.
Unique Solution
AtriAN takes a novel and unique approach to the resolution of the disease by targeting and disabling the hyperactive signals responsible for the arrhythmia.
Funding in Place
AtriAN has raised over €5M in funding, bringing us to that exciting stage of first clinical treatments. We are seeking expressions of interest from investors for the next phase of our journey.
Unmet Need
Existing medications have a very high failure rate and affect every organ in the body. Current ablation technologies only seek to block the signals responsible for this condition; this results in recurrence rates that are far too high.
First In Human (FIH) Trials
AtriAN is excited to announce that we have enrolled and treated 36 patients in two First-In-Human (FIH) trials.
Clinical Trials
In addition to our work with Pulsed Field Ablation (PFA), we are progressing our R&D with innovative, unique and minimally-invasive catheters to reach and deliver the energy to the epicardial surface of the heart.
Pulsed Field Ablation (PFA)
This energy is revolutionising the field of electrophysiology due to its safety profile. While most companies replace thermal energy with PFA, on the inside of the heart (endocardial) AtriAN takes it directly to the condition’s origin on the outside (epicardially).
Autonomics Remodeling
Neuromodulation has been one of the most exciting and disruptive approaches to medicine in recent years. Our approach is to restore the autonomic tone of the heart by targeting and disabling the ganglionated plexi (GP) structures.
Sub-Xiphoid Approach
We are using a unique, small incision in the sub-xiphoid region using our small IP-protected catheters.
GENTLE, NON-THERMAL ENERGY
Pulsed Field Cardioneuroablation
AtriAN selectively targets the hyperactive ganglionated plexi (GPs) located on the outside (epicardial) surface of the heart, rebalancing the autonomic tone bringing the heart back to its natural rhythm.
Selectively targets and disables the GPs
Gently spares the myocardium (heart muscle).
Gentle
AtriAN uses Pulsed Field Ablation (PFA) to ablate neuronal cells selectively.
As a result, the other tissues, such as healthy heart muscle, are spared.
As a result, the other tissues, such as healthy heart muscle, are spared.
Non-Thermal
Most ablation techniques use either heat (burning) or cold (freezing) to ablate tissue with an intent to create scar tissue which damage surrounding healthy tissues. Our PFA is non-thermal.
Long-Term
Our unique approach of targeting neuronal cells in clusters known as ganglionated plexi (GPs) should prove, from a “first principles” approach to provide a more durable solution.
Catheters
Unique, IP-Protected Catheters
Our unique and patent-protected catheter designs ensure excellent field coverage using saline-infusion while also ensuring navigation to the local sites.
Our Team
AtriAN team members
Publications
Pulsed Electric Field Ablation of Epicardial Autonomic Ganglia: Computer Analysis of Monopolar Electric Field across the Tissues Involved
Electric Field Models
A González-Suárez, B O’Brien, M O’Halloran et al
Bioengineering 2022
This electric field modelling study assessed the field strength distribution in the epicardial fat pads (where the ganglionated plexi are located) and the underlying myocardium, when monopolar pulses are applied. The field strength tends to concentrate within the fat layer, with a substantial drop off into the myocardium. This effect further explains the observed selectivity of ganglia ablation when the treatment is performed epicardially.
News
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
contact us
Get In Touch
We would love to hear from you. Reach out anytime.
Address
Unit 1,
BIC Centre
Upper Newcastle
Galway Ireland
H91E79C
Visit
Visit us in Galway
Unit 1 (Physical), H91E79C
Unit 204 (Billing), H91W60E
Unit 204 (Billing), H91W60E
Atrian
Unit 1, BIC Centre
Upper Newcastle
Galway, Ireland
H91E79C
Upper Newcastle
Galway, Ireland
H91E79C
This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant No. 879499.